TrialBreast cancer research and treatment2019

Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.

Manuel Ruíz-Borrego et al.PubMed ↗Publisher ↗

No numbers read from the abstract.